Aguillard, A
This is particularly powerful in women with PCOS, perimenopausal weight gain, or metabolic sluggishnesswhere balancing hormones and blood sugar is key
Speak to a healthcare professional
Conclusion As the multi-hit hypothesis holds, combining the therapeutic approaches of GLP-1 agonists with resmetirom seems like a promising strategy by targeting the multifaceted pathophysiology of MASH, which may lead to improved patient outcomes
In a published Phase 2 trial (48 weeks), adults with obesity who took retatrutide lost, on average, more weight at higher doses, with the 12 mg group showing 24.2% average weight change at 48 weeks (compared with 2.1% in the placebo group)
Heart failure: promotes sodium and water excretion, reducing cardiac workload, and lowering risk of hospitalization and cardiovascular death